| Fox Chase Cancer Center Patent applications |
| Patent application number | Title | Published |
|---|
| 20120084011 | METHODS FOR MANAGING CANCER PATIENT CARE - Methods for managing the care of a cancer patient are provided. Generally, the methods comprise calculating a risk score from characteristics obtained from a cancer patient with a plurality of nomograms comprising the characteristics and a plurality of competing risk factors, using a program to calculate risk scores; determining the patient's prognosis based on the risk score; and treating the patient with a regimen capable of improving the prognosis of a cancer patient having substantially the same risk score. Systems and computer readable media for practicing the methods are also provided. | 04-05-2012 |
| 20110307967 | TetO-p16 Transgenic Mice - Mice comprising a human p16 transgene operably linked to an inducible promoter and capable of controlled expression of p16 are provided. Also provided are cells, tissues, and organs obtainable from such mice, and methods for producing p16 transgenic mice. | 12-15-2011 |
| 20110207816 | ALTERNATE MORPHEEINS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES - A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms on a condition that in the multimeric protein (1) a structure of each of the units determines a structure of the different quaternary isoforms, (2) the units are in the equilibrium and (3) the structure of the different quaternary isoforms influences a function of the multimeric protein. | 08-25-2011 |
| 20110198516 | SHIELDING FOR COMPACT RADIATION SOURCES - Disclosed are radiation shields substantially enclosing a source of polyenergetic positive ions. The shielding layers are spatially arranged to absorb substantially all unwanted radiation arising directly or indirectly from the polyenergetic positive Also disclosed are methods of shielding unwanted radiation leaking from a system providing a therapeutic dose of polyenergetic positive radiation, as well as shielded polyenergetic positive ion selection systems. | 08-18-2011 |
| 20110189125 | Modulators of HSP70/DnaK Function and Methods of Use Thereof - Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed. | 08-04-2011 |
| 20110172107 | ASSAY FOR IDENTIFYING AGENTS THAT MODULATE EPIGENETIC SILENCING, AND AGENTS IDENTIFIED THEREBY - A high throughput RNAi-based assay for identify factors involved in maintaining epigenetic silencing is disclosed. The assay measures reactivation of a silent reporter gene in cells, resulting from RNAi-based knockdown in target mRNA. RNAi-based screening of these silent reporter cells has identified known enzymes that place or remove epigenetic marks on histones, as well as non-enzymatic proteins that function in silencing or in transfer of marks during S-phase. In addition, the screen has been used to identify a number of novel gene products involved in epigenetic silencing, which are also disclosed. | 07-14-2011 |
| 20110110925 | Compositions and Methods for the Treatment and Diagnosis of Cancer - Compositions and methods for the diagnosis and treatment of cancer, particularly T-ALL, are disclosed. | 05-12-2011 |
| 20100320394 | METHODS AND SYSTEMS FOR INCREASING THE ENERGY OF POSITIVE IONS ACCELERATED BY HIGH-POWER LASERS - The energy of positive ions accelerated in laser-matter interaction experiments can be significantly increased by providing a plurality of laser pulses, e.g., through the process of splitting the incoming laser pulse, to form multiple laser-matter interaction stages. From a thermodynamic point of view, the splitting procedure can be viewed as an effective way of increasing the efficiency of energy transfer from the laser light to positive ions, which energy peaks for processes having the least amount of entropy gain. A 100% increase in the energy efficiency is achieved for a six-stage laser positive ion accelerator compared to a single-stage laser positive ion accelerator. | 12-23-2010 |
| 20100086996 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. | 04-08-2010 |
| 20100086486 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. | 04-08-2010 |
| 20090230318 | TARGET DESIGN FOR HIGH-POWER LASER ACCELERATED IONS - Methods for designing a laser-accelerated ion beam are disclosed. The methods include modeling a system including a heavy ion layer, an electric field, and high energy light positive ions having a maximum light positive ion energy, correlating physical parameters of the heavy ion layer, the electric field, and the maximum light positive ion energy using the model, and varying the parameters of the heavy ion layer to optimize the energy distribution of the high energy light positive ions. One method includes analyzing the acceleration of light positive ions, for example protons, through interaction of a high-power laser pulse with a double-layer target using two-dimensional particle-in-cell (PIC) simulations and a one-dimensional analytical model. The maximum energy acquired by the accelerated light positive ions, e.g., protons, in this model depends on the physical characteristics of the heavy-ion layer—the electron-ion mass ratio and effective charge state of the ions. The hydrodynamic equations for both electron and heavy ion species solved and the test-particle approximation for the protons is applied. It was found that the heavy ion motion modifies the longitudinal electric field distribution, thus changing the acceleration conditions for the light positive ions. | 09-17-2009 |
| 20090050819 | Laser-Accelerated Proton Therapy Units And Superconducting Electromagnet Systems For Same - Compact particle selection and collimation devices are disclosed for delivering beams of protons with desired energy spectra. These devices are useful with laser-accelerated proton therapy systems, in which the initial protons have broad energy and angular distributions. Superconducting magnet systems produce a desired magnetic field configuration to spread the protons with different energies and emitting angles for particle selection. The simulation of proton transport in the presence of the magnetic field shows that the selected protons are successfully refocused on the beam axis after passing through the magnetic field with the optimal magnet system. Dose distributions are also provided using Monte Carlo simulations of the laser-accelerated proton beams for radiation therapy applications. | 02-26-2009 |
| 20090048324 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES - A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms on a condition that in the multimeric protein (1) a structure of each of the units determines a structure of the different quaternary isoforms, (2) the units are in the equilibrium and (3) the structure of the different quaternary isoforms influences a function of the multimeric protein. | 02-19-2009 |
| 20080286847 | ALTERNATE MORPHEEINS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES - A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms on a condition that in the multimeric protein (1) a structure of each of the units determines a structure of the different quaternary isoforms, (2) the units are in the equilibrium and (3) the structure of the different quaternary isoforms influences a function of the multimeric protein. | 11-20-2008 |
| 20080247990 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express a CD16 receptor or an inhibitory killer cell immunoglobulin-like receptor (KIR) on a surface of the cell. In examples, the NK-92 cell is further modified to co-express an associated accessory signaling protein such as FcεRI-γ or TCR-ζ, chemokines, or cytokines such as interleukin-2 (IL-2) or interleukin-15 (IL-15). Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. | 10-09-2008 |
